Anhydro 8-ethyl-5-hydroxy-7-oxo-1,3,4-thiadiazolo<3,2-a>pyrimidinium hydroxide | 39456-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Anhydro 8-ethyl-5-hydroxy-7-oxo-1,3,4-thiadiazolo<3,2-a>pyrimidinium hydroxide
• 英文别名: 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidinium, 8-ethyl-7-hydroxy-5-oxo-, inner salt；8-ethyl-5-oxo-[1,3,4]thiadiazolo[3,2-a]pyrimidin-8-ium-7-olate
• CAS: 39456-06-9
• 化学式: C₇H₇N₃O₂S
• 分子量: 197.217
• InChiKey: CDIDXSSDGQOZSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(乙胺基)-1,3,4-噻二唑 、 二氧化三碳 以 乙醚 为溶剂， 以92%的产率得到Anhydro 8-ethyl-5-hydroxy-7-oxo-1,3,4-thiadiazolo<3,2-a>pyrimidinium hydroxide
  参考文献：
  名称：

  Mesoionic xanthine analogs: antagonists of adenosine receptors

  摘要：

  A variety of mesoionic xanthines including mesoionic thiazolo[3,2-alpha]pyrimidines, benzothiazolopyrimidines, and 1,3,4-thiadiazolo[3,2-alpha]pyrimidines were antagonists of A1-adenosine receptors (inhibition of binding of [3H]-cyclohexyladenosine) and A2-adenosine receptors (inhibition of 2-chloroadenosine-elicited accumulations of cyclic AMP) in brain tissue. Most of the compounds were less potent than theophylline and none were remarkably selective for A1- or A2-adenosine receptors. However, members of the thiadiazolopyrimidine class of mesoionics exhibited very low or no activity as antagonists of A2-adenosine receptors while exhibiting activity only 2-4-fold lower than that of theophylline at A1-adenosine receptors. Unlike the case for theophylline, the presence of a phenyl substituent in the five-membered ring did not enhance the potency of a mesoionic thiadiazolopyrimidine. The nature of the substituents on the mesoionic ring did not appear to have marked effects on potency unlike the marked effect of the nature of 1,3-substituents on activity of nonmesoionic xanthines. The benzothiazolo[3,2-alpha]pyrimidines were the most potent antagonists, being nearly as potent as theophylline at A1-adenosine receptors and somewhat more potent than theophylline at A2-adenosine receptors.

  DOI：

  10.1021/jm00376a027

文献信息

• Mesoionic isoxazolo[2,3-<i>a</i>]pyrimidinediones and 1,3,4-oxadiazolo[3,2-<i>a</i>]pyrimidinediones as potential adenosine antagonists
  作者：Ihsan A. Shehata、Richard A. Glennon

  DOI：10.1002/jhet.5570240511

  日期：1987.9

  Several derivatives of two novel mesoionic ring systems, i.e., isoxazolo[2,3-a]pyrimidinedione and 1,3,4-oxadiazolo[3,2-a]pyrimidinedione, were prepared for evaluation as adenosine antagonists. Whereas both ring systems are relatively stable when the 6-position (i.e., that position corresponding to the purine 1-position) is substituted by an alkyl group, neither ring system is stable when this position

  制备了两种新颖的介电环系统的几种衍生物，即异恶唑并[2,3- a ]嘧啶二酮和1,3,4-恶二唑并[3,2- a ]嘧啶二酮，作为腺苷拮抗剂进行评价。当6-位（即对应于嘌呤1-位的那个位置）被烷基取代时，两个环系统都相对稳定，而当该位置未被取代时，两个环系统都不是稳定的。6-未取代的非内消旋异恶唑并嘧啶二酮的实例表现出相似的行为。作为腺苷拮抗剂，发现中离子化合物的效力不及之前评估的中离子噻二唑[3,2- a ]嘧啶二酮类似物。
• Mesoionic purinone analogs. III. The synthesis and properties of mesoionic thiazolo[3,2-<i>a</i>] pyrimidine-5,7-diones
  作者：R. A. Coburn、R. A. Glennon

  DOI：10.1002/jhet.5570100412

  日期：1973.8

  A number of mesoionic thiazolo[3,2-a ]pyrimidine-5,7-diones, isoconjugate mesoionic analogs of xanthinc, were prepared by the condensation of 2-alkylaminothiazoles with bis(2,4,6-trichloro-phenyl)malonate esters. The ground state molecular properties and reactions of these compounds were found to be consistent with predictions based upon previous SCF molecular orbital treatments of the π-systems of

  通过将2-烷基氨基噻唑与双（2,4,6-三氯-苯基）丙二酸酯缩合制备许多介电的噻唑并[3,2 - a ]嘧啶-5,7-二酮，x吨的同共轭介电类似物。 。发现这些化合物的基态分子性质和反应与基于这些类似物的π系统的先前SCF分子轨道处理的预测一致。
• Mesoionic purinone analogs. 7. In vitro antibacterial activity of mesoionic 1,3,4-thiadiazolo[3,2,-a]pyrimidine-5,7-diones
  作者：Robert A. Coburn、Richard A. Glennon、Zdzislaw F. Chmielewicz

  DOI：10.1021/jm00255a029

  日期：1974.9
• SHEHATA, IHSAN A.;GLENNON, RICHARD A., J. HETEROCYCL. CHEM., 24,(1987) N 5, 1291-1295
  作者：SHEHATA, IHSAN A.、GLENNON, RICHARD A.

  DOI：——

  日期：——